China’s drug regulator approves MPOX vaccine for Clinical Trial

This marks a significant development for China, which currently lacks an approved MPOX vaccine.

100
Clinical Trial
Clinical Trial

Last Updated on September 30, 2024 by The Health Master

MPOX vaccine

China has taken a significant step towards combating the global MPOX outbreak with the approval of a domestic vaccine candidate for clinical trials. Developed by Sinopharm, the MPOX vaccine holds the promise of becoming the country’s first experimental dose to battle this deadly disease.

A Domestic Solution to a Global Problem

The vaccine, created by the Shanghai Institute of Biological Products and administered by Sinopharm, is designed to play a crucial role in preventing and controlling MPOX infections.

This marks a significant development for China, which currently lacks an approved MPOX vaccine.

While a few vaccines have been approved in other countries like the United States, Canada, the European Union, Japan, and Russia, China’s domestic vaccine candidate offers hope for a more accessible and tailored solution.

Accelerating Vaccine Development

The National Medical Products Administration, China’s top drug regulator, has implemented streamlined channels to expedite the approval process for novel drugs and vaccines.

This initiative aims to address urgent health needs, such as the MPOX outbreak, and ensure timely access to life-saving treatments.

A Promising Vaccine Candidate

The newly developed vaccine is a replication-deficient vaccine based on the MVA strain.

This description aligns with Jynneos, the world’s first MPOX vaccine approved by the Food and Drug Administration in the United States.

The similarity in vaccine technology suggests that the Chinese vaccine could potentially offer comparable efficacy and safety.

Addressing a Global Health Emergency

The World Health Organization (WHO) declared the MPOX outbreak in Africa a public health emergency of international concern in August 2024.

This designation highlights the severity of the outbreak and the urgent need for effective prevention and control measures.

While the WHO previously declared a global emergency in July 2022, it was lifted in May 2023 due to a decline in international cases.

However, the recent resurgence of cases has prompted renewed concerns.

China’s Response to the MPOX Outbreak

China has reported a significant number of MPOX cases, with over 2,567 confirmed infections by the end of July.

The development of a domestic vaccine is a crucial step in China’s efforts to combat the outbreak and protect its population from the disease.

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.

Disclaimer: This content, provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information. The Health Master does not claim responsibility for this information.

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news